Abstract

Over the last 10 years definite advances have been made in the treatment of advanced hormone-refractory prostate cancer (HRPC). Present chemotherapeutics for HRPC can provide palliation, and as demonstrated by two large recent randomized trials using docetaxel-based therapy, a modest improvement in overall survival. A number of novel therapeutics are becoming standard of care or are under development including novel chemotherapeutics, bisphosphonates, immunotherapeutics, nucleotide-based targeted therapy, endothelin receptor antagonists, and angiogenesis inhibitors. Development of these novel therapeutics will be essential to provide clinicians multiple avenues through which prostate cancer can be effectively treated.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.